bioAffinity Technologies, Inc. Reports 2025 Financial Results and Operational Highlights

bioAffinity Technologies, Inc. reported its financial results for the year ended December 31, 2025. The company experienced an 87% increase in revenue for its CyPath® Lung test, with the number of tests performed rising by 99%. Physician orders for CyPath® Lung also increased by 67%. Despite a 34% decrease in total revenue due to the discontinuation of unprofitable services, the company streamlined operations, leading to a 9% decrease in operating expenses. Key developments in 2025 included leadership appointments, successful financings totaling approximately $16.9 million, and progress in the innovation pipeline for COPD and asthma diagnostics. The company also expanded its global intellectual property portfolio. For 2026, bioAffinity Technologies anticipates over 100% growth in CyPath® Lung unit sales and revenues. The company is initiating a longitudinal study for CyPath® Lung and exploring collaborations to expand sample collection options. Financial results for 2025 show a net loss of $14.9 million on revenues of $6.2 million, compared to a net loss of $9.0 million on revenues of $9.4 million in 2024. Cash and cash equivalents increased to $6.5 million from $1.1 million.